Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Issue 4 (22nd February 2016)

• Record Type: Journal Article
• Authors: Fannin, RD; Gerrish, K; Sieber, SO; Bushel, PR; Watkins, PB; Paules, RS
• Is Part Of: Clinical pharmacology & therapeutics. Volume 99:Issue 4(2016:Apr.)
• Page Start: 432
• Page End: 441
• Publication Date: 2016-02-22
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.328
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : The diagnosis of drug‐induced liver injury is hindered by the limited utility of clinical chemistries. We have shown that hepatotoxicants can produce peripheral blood transcriptome "signatures" (PBTS) in rodents and humans. In this study, 42 adults were treated with acetaminophen (APAP; 1 g every 6 hours) for seven days, followed by three days of placebo. Eleven subjects received only placebo. After five days, 12 subjects (30%) had increases in serum alanine aminotransferase (ALT) levels ("responders"). PBTS of 707 and 760 genes, respectively, could distinguish responders and nonresponders from placebos. Functional analysis of the responder PBTS revealed increased expression of genes involved in TH2‐mediated and innate immune responses, whereas the nonresponders demonstrated increased gene expression consistent with a tolerogenic immune response. Taken together, these observations suggest that the clinical subjects with transient increases in serum ALT failed to maintain or intensify a hepatic tolerogenic immune response.